Talyta Grippe

Talyta Grippe

Auto-generated profile, based on publicly available information

Talyta Grippe

The University of British Columbia Faculty of Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Tremor and Other Hyperkinetic Movements
Verified
Journal Article
Open access
PDF file
Pedro Renato de Paula BrandãoPedro Renato de Paula Brandão
Pedro Renato de Paula Brandão
TGTalyta C. Grippe
Talyta C. Grippe
Danilo Assis PereiraDanilo Assis Pereira
Danilo Assis Pereira
RMRenato P. Munhoz
Renato P. Munhoz
FCFrancisco Cardoso
Francisco Cardoso
Movement disorders are increasingly described in hospitalized and milder cases of SARS-CoV-2 infection, despite a very low prevalence compared to the total patients. We reviewed the scientific literature published in English, spanning from the initial descriptions of COVID-19 until January 25, 2021, in the PubMed/MEDLINE database. We identified 93 new-onset movement disorders cases (44 articles) from 200 papers screened in the database or reference lists. Myoclonus was present in 63.4% (n = 59), ataxia in 38.7% (n = 36), action/postural tremor in 10.8% (n = 10), rigid-akinetic syndrome in 5.38% (n = 5), oculomotor abnormalities in 20.4% (n = 19), catatonia in 2.1% (n = 2), dystonia in 1.1% (n = 1), chorea in 1.1% (n = 1), functional (psychogenic) movement disorders in 3.2% (n = 3) of the reported COVID-19 cases with any movement disorder. Encephalopathy was a common association (n = 37, 39.78%). Comprehensive neurophysiological, clinical, and neuroimaging descriptions of movement disorders in the setting of SARS-CoV-2 infection are still lacking, and their pathophysiology may be related to inflammatory, postinfectious, or even indirect mechanisms not specific to SARS-CoV-2, such as ischemic-hypoxic brain insults, drug effects, sepsis, kidney failure. Cortical/subcortical myoclonus, which the cited secondary mechanisms can largely cause, seems to be the most common hyperkinetic abnormal movement, and it might occur in association with encephalopathy and ataxia. This brief review contributes to the clinical description of SARS-CoV-2 potential neurological manifestations, assisting clinical neurologists in identifying features of these uncommon syndromes as a part of COVID-19 symptomatology.

24 May 2024 in Movement Disorders
Verified
Journal Article
Open access
TGTalyta Grippe
Talyta Grippe
YSYazan Shamli‐Oghli
Yazan Shamli‐Oghli
GDGhazaleh Darmani
Ghazaleh Darmani
JNJean‐François Nankoo
Jean‐François Nankoo
NRNasem Raies
Nasem Raies
RCRobert Chen
Robert Chen
Background: Low‐intensity transcranial ultrasound stimulation (TUS) is a noninvasive brain stimulation (NIBS) technique with high spatial specificity. Previous studies showed that TUS delivered in a theta burst pattern (tbTUS) increased motor cortex (MI) excitability up to 30 minutes due to long‐term potentiation (LTP)–like plasticity. Studies using other forms of NIBS suggested that cortical plasticity may be impaired in patients with Parkinson's disease (PD).Objective: The aim was to investigate the neurophysiological effects of tbTUS in PD patients off and on dopaminergic medications compared to healthy controls.Methods: We studied 20 moderately affected PD patients in on and off dopaminergic medication states (7 with and 13 without dyskinesia) and 17 age‐matched healthy controls in a case‐controlled study. tbTUS was applied for 80 seconds to the MI. Motor‐evoked potentials (MEP), short‐interval intracortical inhibition (SICI), and short‐interval intracortical facilitation (SICF) were recorded at baseline, and at 5 minutes (T5), T30, and T60 after tbTUS. Motor Unified Parkinson's Disease Rating Scale (mUPDRS) was measured at baseline and T60.Results: tbTUS significantly increased MEP amplitude at T30 compared to baseline in controls and in PD patients on but not in PD patients off medications. SICI was reduced in PD off medications compared to controls. tbTUS did not change in SICI or SICF. The bradykinesia subscore of mUPDRS was reduced at T60 compared to baseline in PD on but not in the off medication state. The presence of dyskinesia did not affect tbTUS‐induced plasticity.Conclusions: tbTUS‐induced LTP plasticity is impaired in PD patients off medications and is restored by dopaminergic medications. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

25 February 2023 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
Pedro Renato de Paula BrandãoPedro Renato de Paula Brandão
Pedro Renato de Paula Brandão
Danilo Assis PereiraDanilo Assis Pereira
Danilo Assis Pereira
TGTalyta Cortez Grippe
Talyta Cortez Grippe
DBDiógenes Diego de Carvalho Bispo
Diógenes Diego de Carvalho Bispo
FMFernando Bisinoto Maluf
Fernando Bisinoto Maluf
FCFrancisco Cardoso
Francisco Cardoso

2 May 2025 in Movement Disorders
Verified
Journal Article
Open access
CSCan Sarica
Can Sarica
KYKazuaki Yamamoto
Kazuaki Yamamoto
CIChristian Iorio-Morin
Christian Iorio-Morin
JGJürgen Germann
Jürgen Germann
AYAndrew Z. Yang
Andrew Z. Yang
ALAndres M Lozano
Andres M Lozano
Background: The efficacy and adverse events (AEs) of bilateral magnetic resonance‐guided focused ultrasound (MRgFUS) thalamotomies for essential tremor (ET) have not been compared to those of deep brain stimulation (DBS). Furthermore, it is uncertain whether second‐side thalamotomies can be positioned differently from the first without compromising effectiveness.Objective: We aimed to indirectly compare bilateral MRgFUS and DBS, while identifying optimal lesion/stimulation locations.Methods: We retrospectively examined 41 ET patients who received either bilateral thalamic DBS (n = 22) or MRgFUS (n = 19) surgery. The primary outcome was the comparison of modalities for change in Clinical Rating Scale for Tremor (CRST) from baseline to post second surgery. We characterized AEs, generated probabilistic maps, and tracked streamlines intersecting lesions. First‐side lesions were always intentionally placed ventrally (z = 0/+2 mm above the intercommissural plane [ICP]), and second‐side lesions were placed dorsally (z = +3 mm above ICP).Results: Tremor scores improved significantly after second surgeries (MRgFUS: 56.3 ± 7.1 to 24.2 ± 10.4, P < 0.001; DBS: 58.8 ± 11.6 to 25.0 ± 13, P < 0.05, mean follow‐up: 23/26 months), with no differences between modalities. Following first surgeries, scores were MRgFUS: 37.9 ± 7.9 and DBS: 35.2 ± 13.6, with significant improvement from baseline (P < 0.001, mean follow‐up: 40/73 months). All AEs were grade 1–2, with AE‐free rates of 41% for DBS and 32% for MRgFUS. First‐side lesions exhibited maximal efficacy in the ventral Vim, extending to posterior subthalamic area (PSA), whereas second‐side lesions demonstrated maximal efficacy in the dorsomedial Vim‐Vop border. DBS maps corroborated this finding and confined to Vim‐Vop border. Lesions intersecting with networks interconnected with the supplementary motor area, in addition to M1, were associated with improved outcomes.Conclusions: The efficacies of bilateral MRgFUS and DBS appear comparable. MRgFUS probabilistic maps vary with different targeting methods, revealing two distinct sweet spots: dorsal Vim‐Vop border and ventral Vim/PSA. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

8 July 2023 in Toxicon
Verified
Journal Article
Closed access
TGTalyta Grippe
Talyta Grippe
RCRobert Chen
Robert Chen

23 May 2024 in Clinical Neurophysiology
Verified
Journal Article
Open access
JLJean-Pascal Lefaucheur
Jean-Pascal Lefaucheur
EMElena Moro
Elena Moro
YSYuichiro Shirota
Yuichiro Shirota
YUYoshikazu Ugawa
Yoshikazu Ugawa
TGTalyta Grippe
Talyta Grippe
WPWalter Paulus
Walter Paulus
In this review, different aspects of the use of clinical neurophysiology techniques for the treatment of movement disorders are addressed. First of all, these techniques can be used to guide neuromodulation techniques or to perform therapeutic neuromodulation as such. Neuromodulation includes invasive techniques based on the surgical implantation of electrodes and a pulse generator, such as deep brain stimulation (DBS) or spinal cord stimulation (SCS) on the one hand, and non-invasive techniques aimed at modulating or even lesioning neural structures by transcranial application. Movement disorders are one of the main areas of indication for the various neuromodulation techniques. This review focuses on the following techniques: DBS, repetitive transcranial magnetic stimulation (rTMS), low-intensity transcranial electrical stimulation, including transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS), and focused ultrasound (FUS), including high-intensity magnetic resonance-guided FUS (MRgFUS), and pulsed mode low-intensity transcranial FUS stimulation (TUS). The main clinical conditions in which neuromodulation has proven its efficacy are Parkinson's disease, dystonia, and essential tremor, mainly using DBS or MRgFUS. There is also some evidence for Tourette syndrome (DBS), Huntington's disease (DBS), cerebellar ataxia (tDCS), and axial signs (SCS) and depression (rTMS) in PD. The development of non-invasive transcranial neuromodulation techniques is limited by the short-term clinical impact of these techniques, especially rTMS, in the context of very chronic diseases. However, at-home use (tDCS) or current advances in the design of closed-loop stimulation (tACS) may open new perspectives for the application of these techniques in patients, favored by their easier use and lower rate of adverse effects compared to invasive or lesioning methods. Finally, this review summarizes the evidence for keeping the use of electromyography to optimize the identification of muscles to be treated with botulinum toxin injection, which is indicated and widely performed for the treatment of various movement disorders.